IBDEI1X2 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32514,0)
 ;;=I87.001^^126^1617^11
 ;;^UTILITY(U,$J,358.3,32514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32514,1,3,0)
 ;;=3^Postrhomb syndr w/o compl of rt lwr extrem
 ;;^UTILITY(U,$J,358.3,32514,1,4,0)
 ;;=4^I87.001
 ;;^UTILITY(U,$J,358.3,32514,2)
 ;;=^5008027
 ;;^UTILITY(U,$J,358.3,32515,0)
 ;;=I80.01^^126^1617^8
 ;;^UTILITY(U,$J,358.3,32515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32515,1,3,0)
 ;;=3^Phlebitis & Thromboph,Right Lower Sprfcl Vessels
 ;;^UTILITY(U,$J,358.3,32515,1,4,0)
 ;;=4^I80.01
 ;;^UTILITY(U,$J,358.3,32515,2)
 ;;=^5007821
 ;;^UTILITY(U,$J,358.3,32516,0)
 ;;=I80.02^^126^1617^6
 ;;^UTILITY(U,$J,358.3,32516,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32516,1,3,0)
 ;;=3^Phlebitis & Thromboph,Left Lower Sprfcl Vessels
 ;;^UTILITY(U,$J,358.3,32516,1,4,0)
 ;;=4^I80.02
 ;;^UTILITY(U,$J,358.3,32516,2)
 ;;=^5007822
 ;;^UTILITY(U,$J,358.3,32517,0)
 ;;=I80.03^^126^1617^4
 ;;^UTILITY(U,$J,358.3,32517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32517,1,3,0)
 ;;=3^Phlebitis & Thromboph,Bilateral Lower Sprfcl Vessels
 ;;^UTILITY(U,$J,358.3,32517,1,4,0)
 ;;=4^I80.03
 ;;^UTILITY(U,$J,358.3,32517,2)
 ;;=^5007823
 ;;^UTILITY(U,$J,358.3,32518,0)
 ;;=I80.11^^126^1617^7
 ;;^UTILITY(U,$J,358.3,32518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32518,1,3,0)
 ;;=3^Phlebitis & Thromboph,Right Femoral Vein
 ;;^UTILITY(U,$J,358.3,32518,1,4,0)
 ;;=4^I80.11
 ;;^UTILITY(U,$J,358.3,32518,2)
 ;;=^5007825
 ;;^UTILITY(U,$J,358.3,32519,0)
 ;;=I80.12^^126^1617^5
 ;;^UTILITY(U,$J,358.3,32519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32519,1,3,0)
 ;;=3^Phlebitis & Thromboph,Left Femoral Vein
 ;;^UTILITY(U,$J,358.3,32519,1,4,0)
 ;;=4^I80.12
 ;;^UTILITY(U,$J,358.3,32519,2)
 ;;=^5007826
 ;;^UTILITY(U,$J,358.3,32520,0)
 ;;=I80.13^^126^1617^3
 ;;^UTILITY(U,$J,358.3,32520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32520,1,3,0)
 ;;=3^Phlebitis & Thromboph,Bilateral Femora Vein
 ;;^UTILITY(U,$J,358.3,32520,1,4,0)
 ;;=4^I80.13
 ;;^UTILITY(U,$J,358.3,32520,2)
 ;;=^5007827
 ;;^UTILITY(U,$J,358.3,32521,0)
 ;;=L98.0^^126^1617^21
 ;;^UTILITY(U,$J,358.3,32521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32521,1,3,0)
 ;;=3^Pyogenic granuloma
 ;;^UTILITY(U,$J,358.3,32521,1,4,0)
 ;;=4^L98.0
 ;;^UTILITY(U,$J,358.3,32521,2)
 ;;=^5009574
 ;;^UTILITY(U,$J,358.3,32522,0)
 ;;=L40.0^^126^1617^16
 ;;^UTILITY(U,$J,358.3,32522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32522,1,3,0)
 ;;=3^Psoriasis vulgaris
 ;;^UTILITY(U,$J,358.3,32522,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,32522,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,32523,0)
 ;;=L40.1^^126^1617^19
 ;;^UTILITY(U,$J,358.3,32523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32523,1,3,0)
 ;;=3^Pustular Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,32523,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,32523,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,32524,0)
 ;;=L40.9^^126^1617^17
 ;;^UTILITY(U,$J,358.3,32524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32524,1,3,0)
 ;;=3^Psoriasis, unspec
 ;;^UTILITY(U,$J,358.3,32524,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,32524,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,32525,0)
 ;;=L40.3^^126^1617^20
 ;;^UTILITY(U,$J,358.3,32525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32525,1,3,0)
 ;;=3^Pustulosis palmaris et plantaris
 ;;^UTILITY(U,$J,358.3,32525,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,32525,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,32526,0)
 ;;=L40.8^^126^1617^15
 ;;^UTILITY(U,$J,358.3,32526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32526,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,32526,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,32526,2)
 ;;=^271917
